These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Tissue inhibitors of matrix metalloproteinase-1 levels are increased in serum of patients with allergic contact dermatitis.
    Author: Reduta T, Laudańska H, Laudanski P.
    Journal: Contact Dermatitis; 2007 Aug; 57(2):100-4. PubMed ID: 17627649.
    Abstract:
    Allergic contact dermatitis (ACD) is an antigen-specific, T-cell-mediated skin inflammatory disease. Matrix metalloproteinases (MMPs) and their tissue inhibitors of matrix metalloproteinases (TIMPs) play a role in degradation of extracellular matrix and subsequent tissue remodelling during inflammatory process. The objective of this study was to examine a possible role of TIMP-1 and MMP-9 in the pathogenesis of ACD. The serum levels of MMP-9 and TIMP-1 have been measured using enzyme-linked immunosorbent assay in patients with disseminated ACD during exacerbation of skin lesions and the remission stage (n= 20) and were compared with healthy subjects (n= 20). The mean serum levels of TIMP-1 were significantly higher in patients with ACD than in control group (42.8 +/- 4.9 ng/ml). This difference was more prominent in patients with ACD during remission (69.01 +/- 6.99 ng/ml, P < 0.0001) than in patients with exacerbation of disease (46.8 +/- 3.6 ng/ml, P= 0.0054). Mean values of serum MMP-9 did not differ significantly between patients with ACD, both in the acute and in the remission stage, compared with healthy persons (P= 0.76 and P= 0.29, respectively). TIMP-1 might be involved in pathogenesis of ACD. It seems that moderately increased levels of TIMP-1 could reflect degree of activity of skin inflammation, whereas markedly increased levels could contribute to the maintenance of the remission of disease.
    [Abstract] [Full Text] [Related] [New Search]